SGLT2 inhibitors have pleiotropic mechanisms that reduce CKD progression and improve survival in heart failure patients, highlighting their role as a cornerstone in HF management.
Beyond their glucose-lowering effects, SGLT2is provide significant benefits in patients with chronic kidney disease (CKD) and HF, reducing the progression of CKD and improving overall survival. The pleiotropic actions of SGLT2is highlight their potential as a cornerstone in HF management. Further research is needed to fully elucidate their mechanisms and optimize their use in clinical practice.
Piperis et al. (Fri,) studied this question.